-
New Phase 2 Trial Explores Adding Pelareorep to Standard Therapy for Advanced Colorectal Cancer
A new open-label Phase 2 study will test whether adding the investigational agent pelareorep to standard FOLFIRI plus bevacizumab improves outcomes for patients with RAS-mutated, microsatellite-stable metastatic colorectal cancer.
-
University of Cincinnati Begins Clinical Trial Targeting Prosthetic Joint Infections
The University of Cincinnati has enrolled its first patients in a new clinical trial aimed at improving treatment for prosthetic joint infections, a persistent challenge in orthopedic care.
-
FDA Advisory Panel Gives Nod to Six Promising Peptides
An FDA advisory panel has expressed support for six peptides, a signal that could pave the way for broader research and future access to these compounds.
-
TearSolutions’ Peptide Therapy Lacripep Moves Into Phase 2 Trial for Neurotrophic Keratitis
TearSolutions is advancing its lacritin-based peptide candidate Lacripep into a Phase 2 clinical trial for neurotrophic keratitis after receiving two supportive FDA designations. The milestone highlights growing momentum for peptide-based approaches to treating serious eye surface disease.
-
Croatian Scientists’ 1990s Peptide Discovery Gains Mainstream Attention in the US
A peptide first identified by Croatian researchers decades ago is now drawing significant interest in the United States, highlighting how foundational science can find new life and application years after its initial discovery.
-
Kither Biotech Completes Phase I Trial for Novel Peptide Therapy KIT2014
Kither Biotech has announced the completion of a Phase I clinical trial for its investigational peptide therapy KIT2014, marking an important step forward in the compound’s development.
-
FDA Panel Set to Reconsider Peptide Restrictions, Signaling Potential for Expanded Access
An FDA panel is expected to revisit prior restrictions on certain peptides, opening the door to potentially more accessible pathways for these compounds. The move suggests regulators are open to reassessing earlier policy decisions.
-
New Clinical Trial Explores Botulinum Toxin for Stroke and Brain Injury-Related Leg Spasticity
A new randomized trial is investigating whether NT 201, a botulinum toxin therapy, can safely and effectively ease lower limb spasticity in people recovering from stroke or traumatic brain injury.
-
New Phase III Trial to Test Innovative Peptide-Free Chemotherapy Delivery for Peritoneal Cancers
A new Phase III trial, IMPACT, is investigating whether delivering mitomycin as a pressurized aerosol directly into the abdominal cavity can improve outcomes for patients with unresectable appendix or colorectal cancer that has spread to the peritoneum.
-
New Clinical Trial Explores Advanced Combination Therapy for Aggressive Lymphoma
A new Phase 3 clinical trial is comparing two promising drug combinations for treating germinal center B-cell-like diffuse large B-cell lymphoma, aiming to improve outcomes for patients with this fast-growing blood cancer.